Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 24-Jan-23 4:03 PM View:  | Sharp Shalini Director | Mirati Therapeutics, Inc. (MRTX) | 20-Jan-23 | Grant | 4,444 | -- | -- | 89% 4.97K to 9.41K | |
| 24-Jan-23 4:00 PM View: | Fuchs Henry J Director | Mirati Therapeutics, Inc. (MRTX) | 20-Jan-23 | Grant | 4,444 | -- | -- | 74% 6.02K to 10.46K | |
| 24-Jan-23 4:00 PM View: | Meek David D. Chief Executive Officer Director | Mirati Therapeutics, Inc. (MRTX) | 20-Jan-23 | Grant | 89,379 | -- | -- | 145% 61.79K to 151.17K | |
| 24-Jan-23 4:00 PM View: | Carter Bruce L A Director | Mirati Therapeutics, Inc. (MRTX) | 20-Jan-23 | Grant | 4,444 | -- | -- | 74% 6.02K to 10.46K | |
| 24-Jan-23 4:00 PM View: | Martinez Maria E Director | Mirati Therapeutics, Inc. (MRTX) | 20-Jan-23 | Grant | 4,444 | -- | -- | 74% 6.02K to 10.46K | |
| 24-Jan-23 4:20 PM View: | Davis Aaron I. Director 10% Owner | Mirati Therapeutics, Inc. (MRTX) | 20-Jan-23 | Grant | 4,444 | -- | -- | 10% 43.07K to 47.52K | |
| 24-Jan-23 4:19 PM View: | Johnson Craig A Director | Mirati Therapeutics, Inc. (MRTX) | 20-Jan-23 | Grant | 4,444 | -- | -- | 74% 6.02K to 10.46K | |
| 24-Jan-23 4:17 PM View: | Hasnain Faheem Director | Mirati Therapeutics, Inc. (MRTX) | 20-Jan-23 | Grant | 6,333 | -- | -- | 73% 8.72K to 15.05K | |
| 24-Jan-23 4:00 PM View: | Christensen Jamie EVP, Chief Scientific Officer | Mirati Therapeutics, Inc. (MRTX) | 20-Jan-23 | Grant | 26,864 | -- | -- | 27% 97.88K to 124.74K | |
| 24-Jan-23 4:18 PM View: | Cherrington Julie M Director | Mirati Therapeutics, Inc. (MRTX) | 20-Jan-23 | Grant | 4,444 | -- | -- | 100% 0 to 4.44K | |
| 24-Jan-23 4:00 PM View: | Hickey Benjamin EVP, Chief Commercial Officer | Mirati Therapeutics, Inc. (MRTX) | 20-Jan-23 | Grant | 36,394 | -- | -- | 77% 47.22K to 83.62K | |
| 24-Jan-23 4:20 PM View: | Baum Charles M President,Founder,Head of R&D Director | Mirati Therapeutics, Inc. (MRTX) | 20-Jan-23 | Grant | 4,444 | -- | -- | 3% 168.78K to 173.22K | |
| 24-Jan-23 4:00 PM View: | Stelzer Laurie CFO | Mirati Therapeutics, Inc. (MRTX) | 20-Jan-23 | Grant | 26,864 | -- | -- | 46% 57.8K to 84.66K | |
| 20-Jan-23 9:20 AM View: | Cherrington Julie M Director | Mirati Therapeutics, Inc. (MRTX) | 18-Jan-23 | Sale (Planned) | 2,546 | $44.66 | $113,704.00 | (100%) 2.55K to 0 | |
| 19-Jan-23 9:45 AM View: | Christensen Jamie EVP, Chief Scientific Officer | Mirati Therapeutics, Inc. (MRTX) | 17-Jan-23 | Sale | 2,245 | $42.38 | $95,142.00 | (2%) 100.12K to 97.88K | |
| 19-Jan-23 9:45 AM View: | Hickey Benjamin EVP, Chief Commercial Officer | Mirati Therapeutics, Inc. (MRTX) | 17-Jan-23 | Sale | 1,566 | $42.38 | $66,366.00 | (3%) 48.79K to 47.22K | |
| 19-Jan-23 9:45 AM View: | Meek David D. Chief Executive Officer Director | Mirati Therapeutics, Inc. (MRTX) | 17-Jan-23 | Sale | 3,179 | $42.38 | $134,715.00 | (5%) 64.97K to 61.79K | |
| 10-Jan-23 5:00 PM View: | Hickey Benjamin EVP, Chief Commercial Officer | Mirati Therapeutics, Inc. (MRTX) | 09-Jan-23 | Sale | 2,088 | $45.37 | $94,732.60 | (4%) 50.88K to 48.79K | |
| 05-Jan-23 5:13 PM View: | Christensen Jamie EVP, Chief Scientific Officer | Mirati Therapeutics, Inc. (MRTX) | 04-Jan-23 | Sale | 1,949 | $46.60 | $90,823.40 | (2%) 102.07K to 100.12K | |
| 05-Jan-23 5:13 PM View: | Baum Charles M President,Founder,Head of R&D Director | Mirati Therapeutics, Inc. (MRTX) | 04-Jan-23 | Sale | 3,648 | $46.60 | $169,997.00 | (2%) 172.43K to 168.78K | |
| 21-Dec-22 9:20 PM View: | Meek David D. Chief Executive Officer Director | Mirati Therapeutics, Inc. (MRTX) | 21-Dec-22 | Sale | 4,616 | $40.41 | $186,552.00 | (7%) 69.59K to 64.97K | |
| 21-Dec-22 9:20 PM View: | Hickey Benjamin EVP, Chief Commercial Officer | Mirati Therapeutics, Inc. (MRTX) | 21-Dec-22 | Sale | 3,248 | $40.41 | $131,266.00 | (6%) 54.13K to 50.88K | |
| 21-Dec-22 9:21 PM View: | Baum Charles M President,Founder,Head of R&D Director | Mirati Therapeutics, Inc. (MRTX) | 21-Dec-22 | Sale | 9,092 | $40.42 | $367,469.00 | (5%) 181.52K to 172.43K | |
| 21-Dec-22 9:20 PM View: | Hickey Benjamin EVP, Chief Commercial Officer | Mirati Therapeutics, Inc. (MRTX) | 19-Dec-22 | Grant | 19,149 | -- | -- | 55% 34.98K to 54.13K | |
| 21-Dec-22 9:21 PM View: | Baum Charles M President,Founder,Head of R&D Director | Mirati Therapeutics, Inc. (MRTX) | 19-Dec-22 | Grant | 53,618 | -- | -- | 42% 127.9K to 181.52K | |
| 21-Dec-22 9:20 PM View: | Meek David D. Chief Executive Officer Director | Mirati Therapeutics, Inc. (MRTX) | 19-Dec-22 | Grant | 35,425 | -- | -- | 104% 34.16K to 69.59K | |
| 20-Dec-22 4:02 PM View: | Christensen Jamie EVP, Chief Scientific Officer | Mirati Therapeutics, Inc. (MRTX) | 16-Dec-22 | Sale | 2,410 | $43.00 | $103,624.00 | (2%) 104.48K to 102.07K | |
| 05-Dec-22 5:00 PM View: | Christensen Jamie EVP, Chief Scientific Officer | Mirati Therapeutics, Inc. (MRTX) | 02-Dec-22 | Sale | 1,726 | $90.19 | $155,667.00 | (2%) 106.21K to 104.48K | |
| 28-Nov-22 7:01 PM View: | Baum Charles M President,Founder,Head of R&D Director | Mirati Therapeutics, Inc. (MRTX) | 28-Nov-22 | Planned Option Sale | 69,256 | $100.00 | $6,925,600.00 | (35%) 197.16K to 127.9K | |
| 28-Nov-22 7:01 PM View: | Baum Charles M President,Founder,Head of R&D Director | Mirati Therapeutics, Inc. (MRTX) | 28-Nov-22 | Option Exercise | 69,256 | $17.41 | $1,205,750.00 | 54% 127.9K to 197.16K | |
| 08-Nov-22 6:00 PM View: | Sandler Alan B. Chief Medical Officer | Mirati Therapeutics, Inc. (MRTX) | 07-Nov-22 | Grant | 40,000 | -- | -- | 100% 0 to 40.0K | |
| 09-Sep-22 5:35 PM View: | Christensen Jamie EVP, Chief Scientific Officer | Mirati Therapeutics, Inc. (MRTX) | 07-Sep-22 | Grant | 19,149 | -- | -- | 22% 86.94K to 106.09K | |
| 16-Aug-22 4:15 PM View: | Carter Bruce L A Director | Mirati Therapeutics, Inc. (MRTX) | 12-Aug-22 | Option Sale | 10,000 | $85.49 | $854,899.00 | (62%) 16.02K to 6.02K | |
| 16-Aug-22 4:15 PM View: | Carter Bruce L A Director | Mirati Therapeutics, Inc. (MRTX) | 12-Aug-22 | Option Exercise | 10,000 | $27.00 | $270,000.00 | 166% 6.02K to 16.02K | |
| 03-Jun-22 5:56 PM View: | Stelzer Laurie CFO | Mirati Therapeutics, Inc. (MRTX) | 01-Jun-22 | Grant | 57,798 | -- | -- | 100% 0 to 57.8K | |
| 14-Jun-22 4:35 PM View: | Christensen Jamie EVP, Chief Scientific Officer | Mirati Therapeutics, Inc. (MRTX) | 23-May-22 | Sale | 624 | $63.54 | $39,649.00 | (< 1%) 87.43K to 86.8K | |
| 14-Feb-22 4:51 PM View: | Fuchs Henry J Director | Mirati Therapeutics, Inc. (MRTX) | 11-Feb-22 | Option Exercise | 11,000 | $20.54 | $225,940.00 | 183% 6.02K to 17.02K | |
| 14-Feb-22 4:51 PM View: | Fuchs Henry J Director | Mirati Therapeutics, Inc. (MRTX) | 11-Feb-22 | Planned Option Sale | 11,000 | $105.61 | $1,161,720.00 | (65%) 17.02K to 6.02K | |
| 20-Jan-22 4:57 PM View: | Cherrington Julie M Director | Mirati Therapeutics, Inc. (MRTX) | 19-Jan-22 | Market Sale (Planned) | 1,475 | $116.07 | $171,203.00 | (37%) 4.02K to 2.55K | (7%) |
| 18-Jan-22 8:33 PM View: | Christensen Jamie EVP, Chief Scientific Officer | Mirati Therapeutics, Inc. (MRTX) | 18-Jan-22 | Sale | 627 | $120.51 | $75,557.70 | (< 1%) 88.06K to 87.43K | |
| 18-Jan-22 8:34 PM View: | Reed Vickie S SVP, Chief Accounting Officer | Mirati Therapeutics, Inc. (MRTX) | 18-Jan-22 | Sale | 533 | $120.48 | $64,217.20 | (3%) 15.9K to 15.37K | |
| 18-Jan-22 8:32 PM View: | Baum Charles M President,Founder,Head of R&D Director | Mirati Therapeutics, Inc. (MRTX) | 18-Jan-22 | Option Sale | 2,517 | $120.48 | $303,253.00 | (2%) 130.42K to 127.9K | |
| 18-Jan-22 8:32 PM View: | Baum Charles M President,Founder,Head of R&D Director | Mirati Therapeutics, Inc. (MRTX) | 18-Jan-22 | Option Exercise | 3,703 | $27.00 | $99,981.00 | 3% 126.71K to 130.42K | |
| 18-Jan-22 8:32 PM View: | Hickey Benjamin EVP, Chief Commercial Officer | Mirati Therapeutics, Inc. (MRTX) | 18-Jan-22 | Sale | 627 | $120.48 | $75,542.70 | (2%) 35.6K to 34.98K | |
| 18-Jan-22 8:34 PM View: | Reed Vickie S SVP, Chief Accounting Officer | Mirati Therapeutics, Inc. (MRTX) | 14-Jan-22 | Grant | 5,377 | -- | -- | 51% 10.53K to 15.9K | |
| 18-Jan-22 6:21 PM View: | Carter Bruce L A Director | Mirati Therapeutics, Inc. (MRTX) | 14-Jan-22 | Grant | 2,546 | -- | -- | 73% 3.48K to 6.02K | |
| 18-Jan-22 8:32 PM View: | Baum Charles M President,Founder,Head of R&D Director | Mirati Therapeutics, Inc. (MRTX) | 14-Jan-22 | Grant | 25,543 | -- | -- | 25% 101.17K to 126.71K | |
| 18-Jan-22 6:21 PM View: | Fuchs Henry J Director | Mirati Therapeutics, Inc. (MRTX) | 14-Jan-22 | Grant | 2,546 | -- | -- | 73% 3.48K to 6.02K | |
| 18-Jan-22 6:17 PM View: | Davis Aaron I. Director 10% Owner | Mirati Therapeutics, Inc. (MRTX) | 14-Jan-22 | Grant | 2,546 | -- | -- | 6% 40.53K to 43.07K | |
| 18-Jan-22 6:20 PM View: | Johnson Craig A Director | Mirati Therapeutics, Inc. (MRTX) | 14-Jan-22 | Grant | 2,546 | -- | -- | 73% 3.48K to 6.02K |
